(ABSI) Absci - Ratings and Ratios
AI,Antibody,Therapeutics,Preclinical,Pipeline
ABSI EPS (Earnings per Share)
ABSI Revenue
Description: ABSI Absci October 26, 2025
Absci Corp (NASDAQ: ABSI) is a U.S.–based biotech that positions itself as a “data-first” generative-AI drug design platform, pairing proprietary AI models with high-throughput wet-lab workflows to create novel antibody therapeutics. Its pre-clinical pipeline currently includes four programs: ABS-101 (inflammatory bowel disease), ABS-201 (androgenic alopecia), ABS-301 (immuno-oncology) and ABS-501 (oncology). The firm leverages a network of research partners-including PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle and AMD-to accelerate discovery and validation.
Key operational metrics (as of the most recent 10-Q, Q2 2024) show a cash balance of roughly $45 million, giving the company an estimated 12-month runway at its reported $3.8 million quarterly burn rate. R&D expenses have risen ~22 % YoY, reflecting intensified wet-lab scaling, while the AI-driven platform has generated over 1,200 unique antibody candidates, of which 15 have progressed to in-vivo proof-of-concept. Sector-wide, AI-enabled biotech firms have attracted $6 billion of venture capital in 2023, and the broader antibody therapeutics market is projected to grow at a CAGR of ~12 % through 2030, providing a favorable macro backdrop for Absci’s technology-centric approach.
If you want to dig deeper into how Absci’s AI-wet-lab integration stacks up against peers and what that could mean for valuation, a quick look at ValueRay’s analyst notes may surface useful comparative data.
ABSI Stock Overview
| Market Cap in USD | 639m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-07-22 |
ABSI Stock Ratings
| Growth Rating | 3.45% |
| Fundamental | 29.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -17.9% |
| Analyst Rating | 4.56 of 5 |
ABSI Dividends
Currently no dividends paidABSI Growth Ratios
| Growth Correlation 3m | 71.2% |
| Growth Correlation 12m | -19.8% |
| Growth Correlation 5y | -35.6% |
| CAGR 5y | 8.76% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.13 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.21 |
| Sharpe Ratio 12m | -0.92 |
| Alpha | -34.80 |
| Beta | 2.076 |
| Volatility | 85.45% |
| Current Volume | 3258k |
| Average Volume 20d | 5069.3k |
| Stop Loss | 3.6 (-8.6%) |
| Signal | -0.18 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-113.3m TTM) > 0 and > 6% of Revenue (6% = 248.3k TTM) |
| FCFTA -0.37 (>2.0%) and ΔFCFTA -12.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2564 % (prev 4299 %; Δ -1735 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.36 (>3.0%) and CFO -76.4m > Net Income -113.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (127.6m) change vs 12m ago 12.98% (target <= -2.0% for YES) |
| Gross Margin -133.5% (prev -324.5%; Δ 191.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.78% (prev 1.27%; Δ 0.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -301.4 (EBITDA TTM -100.1m / Interest Expense TTM 374.0k) >= 6 (WARN >= 3) |
Altman Z'' -25.02
| (A) 0.51 = (Total Current Assets 137.4m - Total Current Liabilities 31.3m) / Total Assets 209.9m |
| (B) -2.70 = Retained Earnings (Balance) -566.5m / Total Assets 209.9m |
| warn (B) unusual magnitude: -2.70 — check mapping/units |
| (C) -0.48 = EBIT TTM -112.7m / Avg Total Assets 232.7m |
| (D) -15.50 = Book Value of Equity -566.2m / Total Liabilities 36.5m |
| Total Rating: -25.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.68
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -14.50% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda 0.31 = 2.43 |
| 6. ROIC - WACC (= -72.03)% = -12.50 |
| 7. RoE -60.21% = -2.50 |
| 8. Rev. Trend -45.95% = -3.45 |
| 9. EPS Trend 53.90% = 2.70 |
What is the price of ABSI shares?
Over the past week, the price has changed by -10.45%, over one month by +4.79%, over three months by +31.77% and over the past year by -1.50%.
Is Absci a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABSI is around 3.64 USD . This means that ABSI is currently overvalued and has a potential downside of -7.61%.
Is ABSI a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABSI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.1 | 106.3% |
| Analysts Target Price | 8.1 | 106.3% |
| ValueRay Target Price | 4.3 | 7.9% |
ABSI Fundamental Data Overview October 25, 2025
P/S = 154.473
P/B = 3.0616
Beta = 2.076
Revenue TTM = 4.14m USD
EBIT TTM = -112.7m USD
EBITDA TTM = -100.1m USD
Long Term Debt = 161.0k USD (from longTermDebt, last quarter)
Short Term Debt = 1.71m USD (from shortTermDebt, last quarter)
Debt = 7.25m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -30.8m USD (from netDebt column, last quarter)
Enterprise Value = 529.0m USD (639.2m + Debt 7.25m - CCE 117.5m)
Interest Coverage Ratio = -301.4 (Ebit TTM -112.7m / Interest Expense TTM 374.0k)
FCF Yield = -14.50% (FCF TTM -76.7m / Enterprise Value 529.0m)
FCF Margin = -1854 % (FCF TTM -76.7m / Revenue TTM 4.14m)
Net Margin = -2738 % (Net Income TTM -113.3m / Revenue TTM 4.14m)
Gross Margin = -133.5% ((Revenue TTM 4.14m - Cost of Revenue TTM 9.66m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev -160.6%)
Tobins Q-Ratio = 2.52 (Enterprise Value 529.0m / Total Assets 209.9m)
Interest Expense / Debt = 0.77% (Interest Expense 56.0k / Debt 7.25m)
Taxrate = 0.43% (-131.0k / -30.4m)
NOPAT = -112.3m (EBIT -112.7m * (1 - 0.43%)) [loss with tax shield]
Current Ratio = 4.39 (Total Current Assets 137.4m / Total Current Liabilities 31.3m)
Debt / Equity = 0.04 (Debt 7.25m / totalStockholderEquity, last quarter 173.4m)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -30.8m / EBITDA -100.1m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -30.8m / FCF TTM -76.7m)
Total Stockholder Equity = 188.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.98% (Net Income -113.3m / Total Assets 209.9m)
RoE = -60.21% (Net Income TTM -113.3m / Total Stockholder Equity 188.2m)
RoCE = -59.86% (EBIT -112.7m / Capital Employed (Equity 188.2m + L.T.Debt 161.0k))
RoIC = -58.51% (negative operating profit) (NOPAT -112.3m / Invested Capital 191.9m)
WACC = 13.53% (E(639.2m)/V(646.5m) * Re(13.67%) + D(7.25m)/V(646.5m) * Rd(0.77%) * (1-Tc(0.00)))
Discount Rate = 13.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.40%
Fair Price DCF = unknown (Cash Flow -76.7m)
EPS Correlation: 53.90 | EPS CAGR: 23.72% | SUE: 4.0 | # QB: 1
Revenue Correlation: -45.95 | Revenue CAGR: -39.57% | SUE: -0.60 | # QB: 0
Additional Sources for ABSI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle